Table 4.
Treatment compliance.
| Variables | Eze/Ros 10/20 mg + Tel 80 mg (n = 60) | Eze/Ros 10/20 mg (n = 60) |
Tel 80 mg (n = 60) |
Total (n = 180) |
p-Value |
|---|---|---|---|---|---|
| Compliance at week 4 (week 0~week 4) | 97.50 ± 7.09 | 97.28 ± 3.59 | 97.93 ± 4.18 | 97.56 ± 5.18 | 0.3059 |
| Subjects with Compliance ≥ 80% at week 4, n (%) | 59 (98.33) | 59 (98.33) | 55 (91.67) | 173 (96.11) | NC |
| Compliance at week 8 (week 4~week 8) | 97.20 ± 4.26 | 98.39 ± 3.08 | 97.78 ± 4.06 | 97.79 ± 3.84 | 0.3701 |
| Subjects with Compliance ≥ 80% at week 8, n (%) | 58 (96.67) | 58 (96.67) | 55 (91.67) | 171 (95.00) | NC |
| Overall Compliance | 97.16 ± 4.55 | 97.87 ± 2.48 | 96.62 ± 8.21 | 97.21 ± 5.60 | 0.4567 |
| Subjects with Compliance ≥ 80%, n (%) | 60 (100.00) | 60 (100.00) | 58 (96.67) | 178 (98.89) | 0.3296 |
Abbreviations: Eze, ezetimibe; Ros, rosuvastatin; Tel, telmisartan.